DSI
ALNY icon

Daiwa SB Investments’s Alnylam Pharmaceuticals ALNY Stock Holding History

Daiwa SB Investments’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3,556
Closed -$182K – 243
2017
Q1 		$182K Sell
3,556
-4,555
-56% -$211K 0.05% 130
2016
Q4 		$304K Buy
8,111
+3,300
+69% +$138K 0.08% 114
2016
Q3 		$326K Buy
+4,811
New +$339K 0.08% 117

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Daiwa SB Investments's ALNY Position: Q2 2017 in Review

Daiwa SB Investments sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2017, closing a stake of 3,556 shares — an estimated $182K sold.

Daiwa SB Investments first reported a position in ALNY in Q3 2016 and held it in 3 quarters. The position peaked at $326K in Q3 2016. 227 funds tracked by Wall St. Rank hold ALNY as of Q2 2017.

  • Daiwa SB Investments reported no remaining Alnylam Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Daiwa SB Investments sold 3,556 Alnylam Pharmaceuticals shares in Q2 2017, an estimated $182K.
  • Daiwa SB Investments first reported a position in Alnylam Pharmaceuticals in Q3 2016 and held it in 3 quarters.
  • Daiwa SB Investments's Alnylam Pharmaceuticals position peaked at $326K in Q3 2016.
  • 227 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2017.

Based on Daiwa SB Investments's 13F filing for Q2 2017, filed 11 Jul 2017.